Introduction

Gemtor 1 gm Injection represents a significant advancement in oncology treatment, offering a higher-dose gemcitabine formulation for healthcare providers treating various cancer types. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied by Orio Pharma, this premium oncology medication is designed to provide optimal therapeutic outcomes while maintaining the highest quality standards. With worldwide delivery within 3-7 working days, Gemtor ensures that critical cancer treatments reach patients when they need them most.

Mechanism of Action

Gemtor (Gemcitabine) works through multiple sophisticated mechanisms to target cancer cells effectively:

• Cell Cycle Disruption: Actively kills cells undergoing DNA synthesis and blocks progression through the G1/S-phase boundary
• Metabolic Activation: Converts to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides via nucleoside kinases
• Enzyme Inhibition: The diphosphate form inhibits ribonucleotide reductase, which catalyzes reactions generating deoxynucleoside triphosphates for DNA synthesis
• Competitive Incorporation: Gemcitabine triphosphate competes with dCTP for incorporation into cancer cell DNA
• Self-Potentiation: Reduction in intracellular dCTP concentration enhances gemcitabine triphosphate incorporation into DNA
• Apoptosis Induction: After incorporation into DNA, only one additional nucleotide is added to growing DNA strands, triggering apoptotic cell death

This multi-faceted approach makes Gemtor 1 gm an essential component in modern oncology treatment protocols across multiple cancer types.

Therapeutic Applications

Gemtor 1 gm is indicated for several challenging cancer types:

Ovarian Cancer

• Combination therapy with carboplatin
• Specifically for advanced ovarian cancer with relapse ≥6 months after platinum-based therapy
• Provides renewed therapeutic options for patients with recurrent disease

Breast Cancer

• Combination therapy with paclitaxel
• First-line treatment for metastatic breast cancer after failure of anthracycline-containing adjuvant chemotherapy
• Alternative when anthracyclines are clinically contraindicated

Non-Small Cell Lung Cancer

• Combination therapy with cisplatin
• Standard component of treatment protocols for this prevalent cancer type
• Demonstrated efficacy in improving survival metrics

Pancreatic Cancer

• Single-agent therapy
• Critical treatment option for one of oncology’s most challenging malignancies
• Proven benefits in both quality of life and survival parameters

Dosage Regimens

Gemtor 1 gm allows for precise dosing across different cancer types:

Ovarian Cancer: 1000 mg/m² administered over 30 minutes on Days 1 and 8 of each 21-day treatment cycle

Breast Cancer: 1250 mg/m² administered over 30 minutes on Days 1 and 8 of each 21-day treatment cycle

Non-Small Cell Lung Cancer: Two dosing options:

• 1000 mg/m² over 30 minutes on Days 1, 8, and 15 of each 28-day cycle, or
• 1250 mg/m² over 30 minutes on Days 1 and 8 of each 21-day cycle

Pancreatic Cancer: 1000 mg/m² over 30 minutes once weekly for 7 weeks, followed by one week rest, then once weekly for 3 weeks of each subsequent 28-day cycle

The higher 1 gm concentration provides flexibility in preparing accurate doses for various patient needs while reducing the volume of solution required for administration.

Clinical Considerations

Contraindications

Gemtor is contraindicated in patients with known hypersensitivity to gemcitabine or any components of the formulation.

Safety Information

Healthcare providers should be aware of these important safety considerations:

• Schedule-Dependent Toxicity: Toxicity increases with infusion times >60 minutes or more frequent than weekly dosing
• Myelosuppression Monitoring: Regular blood count monitoring is essential prior to each cycle
• Pulmonary Concerns: Discontinue immediately for unexplained dyspnea or evidence of severe pulmonary toxicity
• Renal Function: Monitor for Hemolytic-Uremic Syndrome (HUS) and discontinue for HUS or severe renal impairment
• Pregnancy Category D: Can cause fetal harm; contraindicated during pregnancy
• Lactation Considerations: Not recommended during breastfeeding due to potential risks to nursing infants

Adverse Reactions

Patients may experience:

• Gastrointestinal effects (nausea/vomiting)
• Hematological changes (anemia, neutropenia, thrombocytopenia)
• Hepatic effects (transaminitis)
• Elevated alkaline phosphatase
• Renal effects (proteinuria, hematuria)
• Fever and rash
• Respiratory symptoms (dyspnea)
• Peripheral edema

Storage and Handling

To maintain optimal efficacy and safety:

• Store below 30°C
• Protect from light exposure
• Keep away from moisture
• Store securely out of reach of children
• Follow institutional guidelines for handling cytotoxic agents

Pharmaceutical Excellence

Gemtor 1 gm is manufactured by Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh with over three decades of experience in producing world-class medications. Since its inception in 1990, when it acquired the Bangladesh operation of SK&F, USA, Eskayef has established itself as a beacon of premium quality in pharmaceutical manufacturing. The company’s commitment to excellence ensures that each vial of Gemtor 1 gm meets the highest international standards for efficacy, safety, and quality.

Supplier

Orio Pharma serves as the dedicated supplier for Gemtor 1 gm, specializing in anti-cancer and oncology medicines since 2019. Founded on the principles of compassion, integrity, innovation, and collaboration, Orio Pharma is committed to making life-saving medications accessible to patients worldwide. Their reliable global logistics network ensures delivery within 3-7 working days, addressing the critical time sensitivity of cancer treatments.

Conclusion

Gemtor 1 gm (Gemcitabine) Injection represents a cornerstone in modern oncology treatment, offering healthcare providers a powerful tool against multiple cancer types. With its higher concentration formulation, comprehensive mechanism of action, and reliable manufacturing and supply chain, it stands as an essential component in the fight against ovarian, breast, lung, and pancreatic cancers. Backed by Eskayef Pharmaceuticals’ three decades of manufacturing excellence and Orio Pharma’s dedicated oncology focus, Gemtor 1 gm delivers the quality, efficacy, and reliability that healthcare professionals and patients depend on during cancer treatment.

For complete prescribing information, clinical support, or to place an order, healthcare professionals are encouraged to contact Orio Pharma’s specialized oncology team today.